NASDAQ:CERN - Cerner Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$61.03 -0.44 (-0.72 %)
(As of 07/17/2018 04:04 AM ET)
Previous Close$61.47
Today's Range$60.91 - $61.50
52-Week Range$52.05 - $73.86
Volume1.19 million shs
Average Volume2.48 million shs
Market Capitalization$20.40 billion
P/E Ratio27.74
Dividend YieldN/A
Beta0.96
Cerner logoCerner Corporation provides health care information technology solutions and services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It also provides HealtheIntent platform, a cloud-based platform that enables organizations to aggregate, transform, and reconcile data across the continuum of care, as well as EHR agnostic platform, CareAware, that facilitates connectivity of health care devices to EHRs. In addition, the company offers a portfolio of clinical and financial health care information technology solutions, as well as departmental, connectivity, population health, and care coordination solutions; and various complementary services, including support, hosting, managed, implementation, and strategic consulting services. Further, it provides various services, such as implementation and training, remote hosting, operational management, revenue cycle, support and maintenance, health care data analysis, clinical process optimization, transaction processing, employer health centers, employee wellness programs, and third party administrator services for employer-based health plans; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. Cerner Corporation was founded in 1979 and is headquartered in North Kansas City, Missouri.

Receive CERN News and Ratings via Email

Sign-up to receive the latest news and ratings for CERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Computer integrated systems design
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:CERN
CUSIP15678210
Phone816-221-1024

Debt

Debt-to-Equity Ratio0.09
Current Ratio2.95
Quick Ratio2.93

Price-To-Earnings

Trailing P/E Ratio27.74
Forward P/E Ratio26.77
P/E Growth1.95

Sales & Book Value

Annual Sales$5.14 billion
Price / Sales3.94
Cash Flow$3.9553 per share
Price / Cash15.43
Book Value$14.40 per share
Price / Book4.24

Profitability

EPS (Most Recent Fiscal Year)$2.20
Net Income$866.97 million
Net Margins16.50%
Return on Equity15.80%
Return on Assets11.63%

Miscellaneous

Employees26,000
Outstanding Shares331,810,000
Market Cap$20,396.61

The Truth About Cryptocurrencies

Cerner (NASDAQ:CERN) Frequently Asked Questions

What is Cerner's stock symbol?

Cerner trades on the NASDAQ under the ticker symbol "CERN."

How will Cerner's stock buyback program work?

Cerner declared that its Board of Directors has initiated a stock buyback program on Sunday, June 4th 2017, which allows the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

How were Cerner's earnings last quarter?

Cerner Co. (NASDAQ:CERN) released its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.58 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.58. The business earned $1.29 billion during the quarter, compared to analyst estimates of $1.34 billion. Cerner had a return on equity of 15.80% and a net margin of 16.50%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.59 earnings per share. View Cerner's Earnings History.

When is Cerner's next earnings date?

Cerner is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Cerner.

What guidance has Cerner issued on next quarter's earnings?

Cerner updated its second quarter earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $0.59-0.61 for the period, compared to the Thomson Reuters consensus estimate of $0.66. The company issued revenue guidance of $1.31-1.36 billion, compared to the consensus revenue estimate of $1.38 billion.

What price target have analysts set for CERN?

18 equities research analysts have issued 12-month target prices for Cerner's shares. Their forecasts range from $58.00 to $80.00. On average, they expect Cerner's stock price to reach $69.0464 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Ratings for Cerner.

What is the consensus analysts' recommendation for Cerner?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerner in the last year. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Cerner stock?

Here are some recent quotes from research analysts about Cerner stock:
  • 1. According to Zacks Investment Research, "Cerner Corporation currently rides on its solid international growth, which is likely to boost with the company’s prospects in Australia, U.K. Ireland and Germany. We believe that the company has growth opportunities in the revenue cycle management (RCM), Population Health and ambulatory markets based on its product strength and enviable track record of adding new clients. Solid growth in the HealtheIntent platform also holds promise. Further, the company recently reported a suite of developments in its EHR platform. However, the company has been grappling with software issues and technology resale. Lesser-than-expected subscription bookings mar Cerner’s licensed software sales recently. A downbeat guidance indicates looming concerns ahead. Further, lower margins on technology resale, resulting from higher mix of device resale are a concern. Cerner underperformed its industry in a year's time." (7/3/2018)
  • 2. Cantor Fitzgerald analysts commented, "Our rating remains Overweight and our PT remains $70. Although some amount of investor skepticism regarding the company’s growth outlook continues to temper valuation levels, we do not share those concerns. Our long-term DCF model assumptions are mostly conservative, with high single-digit revenue growth and modest margin expansion. Capital spending should moderate in 2019. We think the shares offer a compelling risk/reward trade off (excluding the potential impact from the VA contract). We value the VA contract at roughly $10 per share, but that estimate can vary based on terms and timing." (5/17/2018)
  • 3. Canaccord Genuity analysts commented, "We reiterate our BUY rating and raise our PT to $73. Not without noise on 4Q’17 and updated guidance, CERN continues to perform in new business wins. Bookings performance was stellar, up 62% y/y on large Works wins with solid growth across many product areas. The delayed Veterans Administration signing and some pre-revenue project investment will likely pressure margins near-term, but will be more than offset on the bottom-line from the tax reform benefit. We normally would be more critical on near-term margin compression; however, given bookings strength and benefits from tax reform, we recommend investors continue to own shares and add to positions. Key positive: Bookings grew 62% to $2.3B, outperforming us and cons. both at $1.8B. 1Q’18 bookings guidance straddled our estimate and con." (2/7/2018)

Who are some of Cerner's key competitors?

Who are Cerner's key executives?

Cerner's management team includes the folowing people:
  • Mr. Clifford W. Illig, Co-Founder & Vice Chairman (Age 67)
  • Mr. Zane M. Burke, Pres (Age 52)
  • Mr. Marc G. Naughton, Exec. VP & CFO (Age 63)
  • Mr. Michael R. Nill, Exec. VP & COO (Age 53)
  • Mr. Jeffrey A. Townsend, Exec. VP & Chief of Innovation (Age 54)

Has Cerner been receiving favorable news coverage?

Media coverage about CERN stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerner earned a coverage optimism score of 0.12 on Accern's scale. They also gave headlines about the company an impact score of 45.39 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Cerner's major shareholders?

Cerner's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include LGT Capital Partners LTD. (0.29%), Riverbridge Partners LLC (0.09%), DnB Asset Management AS (0.06%), Bank of Montreal Can (0.05%), Rockland Trust Co. (0.05%) and Cim LLC (0.04%). Company insiders that own Cerner stock include Clifford W Illig, David Brent Shafer, Denis A Cortese, Gerald E Bisbee, Jr, Jeffrey A Townsend, Julie M Wilson, Linda M Dillman, Marc G Naughton, Michael Nill, Michael R Battaglioli, Neal L Patterson, Randy D Sims, William D Zollars and Zane M Burke. View Institutional Ownership Trends for Cerner.

Which major investors are selling Cerner stock?

CERN stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Webster Bank N. A., Lau Associates LLC, Cape Cod Five Cents Savings Bank, West Coast Financial LLC, Macguire Cheswick & Tuttle Investment Counsel LLC and YHB Investment Advisors Inc.. Company insiders that have sold Cerner company stock in the last year include Clifford W Illig, David Brent Shafer, Denis A Cortese, Jeffrey A Townsend, Marc G Naughton, Michael Nill, Michael R Battaglioli, Randy D Sims, William D Zollars and Zane M Burke. View Insider Buying and Selling for Cerner.

Which major investors are buying Cerner stock?

CERN stock was bought by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., DnB Asset Management AS, Bank of Montreal Can, Rockland Trust Co., Trust Department MB Financial Bank N A, Bright Rock Capital Management LLC, Gateway Investment Advisers LLC and V Wealth Management LLC. View Insider Buying and Selling for Cerner.

How do I buy shares of Cerner?

Shares of CERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerner's stock price today?

One share of CERN stock can currently be purchased for approximately $61.03.

How big of a company is Cerner?

Cerner has a market capitalization of $20.40 billion and generates $5.14 billion in revenue each year. The company earns $866.97 million in net income (profit) each year or $2.20 on an earnings per share basis. Cerner employs 26,000 workers across the globe.

How can I contact Cerner?

Cerner's mailing address is 2800 ROCKCREEK PKWY W0162, NORTH KANSAS CITY MO, 64117. The company can be reached via phone at 816-221-1024 or via email at [email protected]


MarketBeat Community Rating for Cerner (NASDAQ CERN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  786 (Vote Outperform)
Underperform Votes:  474 (Vote Underperform)
Total Votes:  1,260
MarketBeat's community ratings are surveys of what our community members think about Cerner and other stocks. Vote "Outperform" if you believe CERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.